Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.30 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19705372 | 0.83 | TSHR (0.50) | TSHRKDM4EL3MBTL1GABRA1GABRB2 | |
| SCHEMBL13712973 | 0.79 | GABRA1 (0.43) | TSHRL3MBTL1GABRA1GABRB2 | |
| SCHEMBL16114533 | 0.79 | LMNA (0.44) | TSHR | |
| SCHEMBL10247815 | 0.79 | TSHR (0.39) | TSHR | |
| SCHEMBL994607 | 0.76 | TSHR (0.73) | TSHRKDM4EL3MBTL1GABRA1GABRB2 | |
| SCHEMBL10192283 | 0.73 | — | — | |
| Hydrogen Peroxide SCHEMBL3675725 | 0.72 | TSHR (0.74) | TSHRKDM4EL3MBTL1GABRA1GABRB2 | |
| SCHEMBL10246341 | 0.72 | TSHR (0.31) | TSHR | |
| SCHEMBL9204533 | 0.71 | TSHR (0.59) | TSHRKDM4EL3MBTL1GABRA1GABRB2 | |
| SCHEMBL944816 | 0.70 | TSHR (0.64) | TSHRKDM4EL3MBTL1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | TSHR 4051/4885KDM4E 1764/4885L3MBTL1 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.